Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

A WAR AGAINST INFLUENZA VIRUS- TAMIFLU

Akshay U. Bachal*, Sushant D. Bamane, Smita J.Patil, Dr. Rajendra. C. Doijad

Shree Santkrupa College Of Pharmacy, Ghogaon, Karad - 415111.

ABSTRACT

Tamiflu or oseltamivir is one of the blockbuster drugs used for prophylaxis and treatment of flu caused by influenza virus Type A (H1N1) and B. Oseltamivir was invented and patented by Californian company Gilead Sciences in 1996. A Swiss pharmaceutical company Hoffmann-La Roche (Roche)then purchased the rights of it and marketedthis drug worldwide under the trade name ‘Tamiflu’. Roche Company had got approval for Tamiflu by US Food and Drug Administration (FDA)& Europe for prophylaxis in children and adults. The drug is now available in about 80 countries globally, including the US, EU countries, Latin America, Canada, Japan, Australia and Switzerland. This review overlooks on History, mechanism of action, dose, side effects, manufacturing processes, synthetic pathways, Clinical Efficacy and Claims of Tamiflu in treatment of Influenza.

Keywords: Tamiflu, History, Marketing commentary,Clinical Efficacy and Claims, Influenza.


[Full Text Article]